These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32790502)

  • 1. Development of a health communication campaign to promote the Texas prescription monitoring program.
    Mackert M; Pounders K; Brown LE; Kirtz S; Wagner JH; Ring D; Hill L; Wilcox G; Murthy D; Tierney W; Innerarity S; McGlone M; Holleran Steiker LK; DeSalvo K; Bernhardt JM; Pretorius K
    Health Mark Q; 2020; 37(3):222-231. PubMed ID: 32790502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do more robust prescription drug monitoring programs reduce prescription opioid overdose?
    Pardo B
    Addiction; 2017 Oct; 112(10):1773-1783. PubMed ID: 28009931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription opioid misuse and the need to promote medication safety among adolescents.
    Abraham O; Thakur T; Brown R
    Res Social Adm Pharm; 2019 Jul; 15(7):841-844. PubMed ID: 30655180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions.
    Bao Y; Wen K; Johnson P; Jeng PJ; Meisel ZF; Schackman BR
    Health Aff (Millwood); 2018 Oct; 37(10):1596-1604. PubMed ID: 30273045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioids and Pharmacy: PMP Extension Granted.
    Berlin J
    Tex Med; 2019 Aug; 115(8):22. PubMed ID: 31369140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States.
    Chen Q; Larochelle MR; Weaver DT; Lietz AP; Mueller PP; Mercaldo S; Wakeman SE; Freedberg KA; Raphel TJ; Knudsen AB; Pandharipande PV; Chhatwal J
    JAMA Netw Open; 2019 Feb; 2(2):e187621. PubMed ID: 30707224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the use of the prescription monitoring program by prescribers and pharmacists in Texas.
    Thornton JD; Varisco TJ; Downs CG
    Pharmacoepidemiol Drug Saf; 2021 Apr; 30(4):492-503. PubMed ID: 33458926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unsolicited Reporting to Prescribers of Opioid Analgesics by a State Prescription Drug Monitoring Program: An Observational Study with Matched Comparison Group.
    Young LD; Kreiner PW; Panas L
    Pain Med; 2018 Jul; 19(7):1396-1407. PubMed ID: 28383713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Nobody Knows How You're Supposed to Interpret it:" End-user Perspectives on Prescription Drug Monitoring Program in Massachusetts.
    Hong M; Seymour S; Stopka TJ; Bandanza L; Crocker E; Morgan A; Beletsky L
    J Addict Med; 2022 May-Jun 01; 16(3):e171-e176. PubMed ID: 34417413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy.
    Holmgren AJ; Botelho A; Brandt AM
    Am J Public Health; 2020 Aug; 110(8):1191-1197. PubMed ID: 32552023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription opioid misuse among adolescents and emerging adults in the United States: A scoping review.
    Bonar EE; Coughlin L; Roche JS; Philyaw-Kotov ML; Bixler EA; Sinelnikov S; Kolosh A; Cihak MJ; Cunningham RM; Walton MA
    Prev Med; 2020 Mar; 132():105972. PubMed ID: 31904397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Experimental Test of the Effectiveness of Unsolicited Reporting by a Prescription Drug Monitoring Program in Reducing Inappropriate Acquisition of Opioids.
    McDonald DC; Carlson KE; Jalbert SK
    Pain Med; 2019 May; 20(5):944-954. PubMed ID: 29868715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Boxed Warning for Immediate-Release Opioids.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):141-5. PubMed ID: 27301692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Issues Regarding Prescription Opioids.
    American College of Medical Toxicology
    J Med Toxicol; 2016 Mar; 12(1):142-4. PubMed ID: 26732680
    [No Abstract]   [Full Text] [Related]  

  • 16. Systematic Literature Review of Prescription Drug Monitoring Programs.
    Ponnapalli A; Grando A; Murcko A; Wertheim P
    AMIA Annu Symp Proc; 2018; 2018():1478-1487. PubMed ID: 30815193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Prescription Monitoring Programs in Reducing Opioid Prescribing, Dispensing, and Use Outcomes: A Systematic Review.
    Wilson MN; Hayden JA; Rhodes E; Robinson A; Asbridge M
    J Pain; 2019 Dec; 20(12):1383-1393. PubMed ID: 31059823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepancies in addressing overdose prevention through prescription monitoring programs.
    Green TC; Bowman S; Davis C; Los C; McHugh K; Friedmann PD
    Drug Alcohol Depend; 2015 Aug; 153():355-8. PubMed ID: 26048640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid misuse: containing harms.
    Peters-Watral B
    Int J Palliat Nurs; 2016 May; 22(5):213. PubMed ID: 27233007
    [No Abstract]   [Full Text] [Related]  

  • 20. Prescription Opioid Misuse, Abuse, Morbidity, and Mortality: Balancing Effective Pain Management and Safety.
    Cheatle MD
    Pain Med; 2015 Oct; 16 Suppl 1():S3-8. PubMed ID: 26360931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.